VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

被引:93
|
作者
Enterlein, S
Warfield, KL
Swenson, DL
Stein, DA
Smith, JL
Gamble, CS
Kroeker, AD
Iversen, PL
Bavari, S
Mühlberger, E
机构
[1] Univ Marburg, Dept Virol, D-35043 Marburg, Germany
[2] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
[3] AVI BioPharma Inc, Corvallis, OR USA
关键词
D O I
10.1128/AAC.50.3.984-993.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
引用
收藏
页码:984 / 993
页数:10
相关论文
共 50 条
  • [1] Ebola virus L–VP35 structure
    Rebecca Kelsey
    Nature Structural & Molecular Biology, 2022, 29 : 1039 - 1039
  • [2] The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3
    Basler, CF
    Mikulasova, A
    Martinez-Sobrido, L
    Paragas, J
    Mühlberger, E
    Bray, M
    Klenk, HD
    Palese, P
    García-Sastre, A
    JOURNAL OF VIROLOGY, 2003, 77 (14) : 7945 - 7956
  • [3] Naive antibody library derived monoclonal antibody against VP35 of Ebola virus
    Lai, Jing Yi
    Corona, Angela
    Ng, Chong Lee
    Tramontano, Enzo
    Choong, Yee Siew
    Lim, Theam Soon
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 245
  • [4] Ebola virus VP35 blocks stress granule assembly
    Le Sage, Valerie
    Cinti, Alessandro
    McCarthy, Stephen
    Amorim, Raquel
    Rao, Shringar
    Daino, Gian Luca
    Tramontano, Enzo
    Branch, Donald R.
    Mouland, Andrew J.
    VIROLOGY, 2017, 502 : 73 - 83
  • [5] The Ebola virus VP35 protein is a suppressor of RNA silencing
    Haasnoot, Joost
    de Vries, Walter
    Geutjes, Ernst-Jan
    Prins, Marcel
    de Haan, Peter
    Berkhout, Ben
    PLOS PATHOGENS, 2007, 3 (06) : 794 - 803
  • [6] Development of RNA Aptamers Targeting Ebola Virus VP35
    Binning, Jennifer M.
    Wang, Tianjiao
    Luthra, Priya
    Shabman, Reed S.
    Borek, Dominika M.
    Liu, Gai
    Xu, Wei
    Leung, Daisy W.
    Basler, Christopher F.
    Amarasinghe, Gaya K.
    BIOCHEMISTRY, 2013, 52 (47) : 8406 - 8419
  • [7] Ebola virus protein VP35 inhibits activation of the interferon-inducible kinase PKR by RNA
    Eitan, Maayan
    Osman, Farhat
    Namer, Lise Sarah
    Eliahu, Einav
    Banai, Yona
    Kaempfer, Raymond
    CYTOKINE, 2008, 43 (03) : 298 - 298
  • [8] Ebola virus replication is regulated by the phosphorylation of viral protein VP35
    Zhu, Lin
    Gao, Ting
    Yang, Weihong
    Liu, Yaoning
    Liu, Xuan
    Hu, Yong
    Jin, Yanwen
    Li, Ping
    Xu, Ke
    Zou, Gang
    Zhao, Lei
    Cao, Ruiyuan
    Zhong, Wu
    Xia, Xianzhu
    Cao, Cheng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 521 (03) : 687 - 692
  • [9] The Ebola virus VP35 protein functions as a type IIFN antagonist
    Basler, CF
    Wang, XY
    Mühlberger, E
    Volchkov, V
    Paragas, J
    Klenk, HD
    Garcia-Sastre, A
    Palese, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) : 12289 - 12294
  • [10] The Importance of the NP: VP35 Ratio in Ebola Virus Nucleocapsid Formation
    Noda, Takeshi
    Kolesnikova, Larissa
    Becker, Stephan
    Kawaoka, Yoshihiro
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S878 - S883